Study of Oral High/Low-dose Cepharanthine Compared With Placebo in Non Hospitalized Adults With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

August 10, 2022

Study Completion Date

August 10, 2022

Conditions
Asymptomatic COVID-19
Interventions
DRUG

Cepharanthine

Low-dose: Day 1\~5: 20mg, Q8H X 5 days (60mg/day)+SMT

DRUG

Placebo

"Day 1\~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc."

DRUG

Cepharanthine

"High-dose: Day 1\~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc."

Trial Locations (2)

200000

Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine, Shanghai

Unknown

Ren Ji Hospital, School of Medicine, Shanghai Jiao TongUniversity, Shanghai

All Listed Sponsors
collaborator

YUNNAN BAIYAO GROUP CO.,LTD

UNKNOWN

lead

Shanghai Jiao Tong University School of Medicine

OTHER